Shots:

• FDA approves Kyowa Kirin’s Poteligeo drug for R/R Mycosis fungoides (MF) and Sézary syndrome (SS)
• Poteligeo received Orphan Drug designation with addition permission granted on basis of Priority Review and Breakthrough Therapy
• The approval is based on a clinical trial of 372 patients with MF or SS. Study reported mPFS (Poteligeo vs Vorinostat) is 7.6mos vs 3.1mos

/ | Ref: US FDA | Image: BioNJ